HMGCR and ovarian cancer: On that note, enzymes involved in the mevalonate pathway such as HMG-CoA reductase, farnesyl diphosphate synthase, squalene synthase and squalene epoxidase are overexpressed and activated in a number of cancers including breast (Siddiqui et al., 2009), melanoma (Kuzu et al., 2016), glioblastoma (Abate et al., 2017), lung cancer (Wang et al., 2018b), ovarian cancer (de Wolf et al., 2017) colorectal (Duncan et al., 2004) and prostate (Hager et al., 2006).